Follow Us:
Emerging Treatments and Advances in Novel Cancer Therapies for Practicing Physicians and Healthcare Professionals
This webcast is jointly sponsored by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.
 |
 |
This activity is supported in part by independent education grants from Teva Pharmaceuticals, Genentech BioOncology, Celgene Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Inc, Millennium Pharmaceuticals, Novartis Oncology, and Genomic Health.
Specialty: Hematology/Oncology
Release date: April 21, 2014
Valid through: April 21, 2015
Target Audience:
This webcast is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new developments for treatment of solid tumors and hematological malignancies. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.
Program Overview:
This webcast is intended to improve care of patients with hematological malignancies by accelerating adoption of new guidelines and evidence-based practice change. In addition to chemotherapy and targeted therapy of solid tumors and hematological malignancies, this symposium will focus on individualized treatment options. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This program consists of 5 continuing education activites.
Module 1 — A. Tolcher, MD & D. Gerber, MD — 1.0 AMA PRA Category 1™ Credit Hours
Module 2 — M. Overman, MD & M. Javle, MD — 1.25 AMA PRA Category 1™ Credit Hours
Module 4 — T. Hudson, DO & R. Kudchadkar, MD — 1.25 AMA PRA Category 1™ Credit Hours